1
|
Siebolts U, Sperveslage J, Pfarr N. [Report of the Molecular Pathology Working Group of the German Society for Pathology]. Pathologie (Heidelb) 2023; 44:254-255. [PMID: 37875573 DOI: 10.1007/s00292-023-01241-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 10/06/2023] [Indexed: 10/26/2023]
Affiliation(s)
- U Siebolts
- Institut für Pathologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
| | - J Sperveslage
- Institut für Molekularpathologie, Hohenzollernring 64, 48145, Münster, Deutschland
| | - N Pfarr
- Institut für Pathologie, TUM School of Medicine and Health, Technische Universtät München, Trogerstr. 18, München, Deutschland
| |
Collapse
|
2
|
Gempt J, Withake F, Aftahy A, Meyer H, Barz M, Delbridge C, Liesche-Starnecker F, Prokop G, Pfarr N, Schlegel J, Meyer B, Zimmer C, Menze B, Wiestler B. Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapy. ESMO Open 2022; 7:100566. [PMID: 36055049 PMCID: PMC9588899 DOI: 10.1016/j.esmoop.2022.100566] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 07/01/2022] [Accepted: 07/17/2022] [Indexed: 11/03/2022] Open
Abstract
Background Patients and methods Results Conclusions Glioblastoma exhibits significant heterogeneity, from epigenome-wide methylation phenotypes to single molecular targets. Phylogeny showed CDKN2A/B loss and gain of EGFR, PDGFRA, and CDK4 early in tumor development. Intratumoral heterogeneity is of utmost importance for molecular classification as well as for defining therapeutic targets. Assessing single biopsies underestimates the true molecular diversity in a tumor.
Collapse
|
3
|
Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J. Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). NPJ Precis Oncol 2022; 6:36. [PMID: 35681079 PMCID: PMC9184602 DOI: 10.1038/s41698-022-00276-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 04/15/2022] [Indexed: 12/12/2022] Open
Abstract
Homologous repair deficiency (HRD) is present in many cancer types at variable prevalence and can indicate response to platinum-based chemotherapy and PARP inhibition. We developed a tumor classification system based on the loss of function of genes in the homologous recombination repair (HRR) pathway. To this end, somatic and germline alterations in BRCA1/2 and 140 other HRR genes were included and assessed for the impact on gene function. Additionally, information on the allelic hit type and on BRCA1 promoter hypermethylation was included. The HRDsum score including LOH, LST, and TAI was calculated for 8847 tumors of the TCGA cohort starting from genotyping data and for the subcohort of ovarian cancer also starting from WES data. Pan-cancer, deleterious BRCA1/2 alterations were detected in 4% of the tumors, while 18% of the tumors were HRD-positive (HRDsum ≥ 42). Across 33 cancer types, both BRCA1/2 alterations and HRD-positivity were most prevalent in ovarian cancer (20% and 69%). Pan-cancer, tumors with biallelic deleterious alterations in BRCA1/2 were separated strongly from tumors without relevant alterations (AUC = 0.89), while separation for tumors with monoallelic deleterious BRCA1/2 alterations was weak (AUC = 0.53). Tumors with biallelic deleterious alterations in other HHR genes were separated moderately from tumors without relevant alterations (AUC = 0.63), while separation for tumors with such monoallelic alterations was weaker (AUC = 0.57). In ovarian cancer, HRDsum scores calculated from WES data correlated strongly with HRDsum scores calculated from genotyping data (R = 0.87) and were slightly (4%) higher. We comprehensively analyzed HRD scores and their association with mutations in HRR genes in common cancer types. Our study identifies important parameters influencing HRD measurement and argues for an integration of HRDsum score with specific mutational profiles.
Collapse
Affiliation(s)
- E Rempel
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - K Kluck
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - S Beck
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,Center for Personalized Medicine (ZPM) Heidelberg, 69120, Heidelberg, Germany
| | - I Ourailidis
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - D Kazdal
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,German Center for Lung Research (DZL), Heidelberg site, 69120, Heidelberg, Germany
| | - O Neumann
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - A L Volckmar
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - M Kirchner
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - H Goldschmid
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - N Pfarr
- Institute of Pathology, TUM School of Medicine, Technical University of Munich, 81675, Munich, Germany
| | - W Weichert
- Institute of Pathology, TUM School of Medicine, Technical University of Munich, 81675, Munich, Germany.,German Cancer Consortium (DKTK), 69120, Heidelberg, Germany
| | - D Hübschmann
- German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.,Division of Translational Medical Oncology, NCT Heidelberg and DKFZ, 69120, Heidelberg, Germany.,NCT Molecular Diagnostics Program, NCT Heidelberg and DKFZ, 69120, Heidelberg, Germany
| | - S Fröhling
- Center for Personalized Medicine (ZPM) Heidelberg, 69120, Heidelberg, Germany.,German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.,Division of Translational Medical Oncology, NCT Heidelberg and DKFZ, 69120, Heidelberg, Germany.,NCT Molecular Diagnostics Program, NCT Heidelberg and DKFZ, 69120, Heidelberg, Germany
| | - C Sutter
- Institute of Human Genetics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - C P Schaaf
- Center for Personalized Medicine (ZPM) Heidelberg, 69120, Heidelberg, Germany.,Institute of Human Genetics, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - P Schirmacher
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany.,German Cancer Consortium (DKTK), 69120, Heidelberg, Germany
| | - V Endris
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany
| | - A Stenzinger
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany. .,Center for Personalized Medicine (ZPM) Heidelberg, 69120, Heidelberg, Germany. .,German Center for Lung Research (DZL), Heidelberg site, 69120, Heidelberg, Germany. .,German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
| | - J Budczies
- Institute of Pathology, Heidelberg University Hospital, 69120, Heidelberg, Germany. .,Center for Personalized Medicine (ZPM) Heidelberg, 69120, Heidelberg, Germany. .,German Center for Lung Research (DZL), Heidelberg site, 69120, Heidelberg, Germany. .,German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
| |
Collapse
|
4
|
Groll T, Jesinghaus M, Denk D, Schwittlick U, Aupperle-Lellbach H, Sarker R, Mogler C, Pfarr N, Steiger K. Bridging the Species Gap – Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. J Comp Pathol 2022. [DOI: 10.1016/j.jcpa.2021.11.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Weichert W, Bartels S, Baretton G, Braicu E, Demes M, Endris V, Herold S, Heukamp L, Hummel M, Lehmann U, Merkelbach-Bruse S, Pfarr N, Rad R, Sehouli J, Siemanowski J, Stenzinger A, von Schwarzenberg K, Vollbrecht C, Wild P, Zocholl D. 758P Concordance between multiple HRD assays is substantial in high-grade ovarian cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Obermann H, Schmidle P, Steimle-Grauer SA, Pfarr N, Posch C. Exceptional response to anti-PD-1 treatment in a patient with metastatic cutaneous hidradenocarcinoma. Eur J Cancer 2021; 145:143-145. [PMID: 33465705 DOI: 10.1016/j.ejca.2020.12.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 12/13/2020] [Indexed: 11/28/2022]
Affiliation(s)
- H Obermann
- Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Germany
| | - P Schmidle
- Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Germany
| | - S A Steimle-Grauer
- Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Germany
| | - N Pfarr
- Institute for Pathology, Technical University of Munich, Germany
| | - C Posch
- Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK), Technical University of Munich, Germany; Faculty of Medicine, Sigmund Freud University Vienna, Austria.
| |
Collapse
|
7
|
Steiger K, Aupperle-Lellbach H, Gruber-Beckmann B, Reiser M, Wirges N, Weichert W, Pfarr N. Dog Cancer Panel: Targeted Massive Parallel Sequencing Detects Somatic and Germline Mutations. J Comp Pathol 2020. [DOI: 10.1016/j.jcpa.2019.10.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Ortiz-Brüchle N, Muders M, Toma M, Esposito I, Hartmann A, Stöhr R, Reis H, Wild P, Köllermann J, Bremmer F, Leichsenring J, Stenzinger A, Merkelbach-Bruse S, Kirfel S, Perner S, Hartmann N, Roth W, Jung A, Kirchner T, Schwamborn K, Pfarr N, Dahl E, Knüchel R, Gaisa NT. [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]. Urologe A 2019; 59:318-325. [PMID: 31541269 DOI: 10.1007/s00120-019-01046-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged. AIM Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology. METHODS We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions. RESULTS A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available. DISCUSSION So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.
Collapse
Affiliation(s)
- N Ortiz-Brüchle
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - M Muders
- Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - M Toma
- Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - I Esposito
- Institut für Pathologie, Universitätsklinikum Düsseldorf, Heinrich-Heine Universität, Düsseldorf, Deutschland
| | - A Hartmann
- Institut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - R Stöhr
- Institut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - H Reis
- Institut für Pathologie, Universitätsklinikum Essen, Essen, Deutschland
| | - P Wild
- Dr. Senckenbergisches Institut für Pathologie, Frankfurt, Deutschland
| | - J Köllermann
- Dr. Senckenbergisches Institut für Pathologie, Frankfurt, Deutschland
| | - F Bremmer
- Institut für Pathologie, Universitätsklinikum Göttingen, Göttingen, Deutschland
| | - J Leichsenring
- Molekularpathologisches Zentrum, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - A Stenzinger
- Molekularpathologisches Zentrum, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | | | - S Kirfel
- Institut für Pathologie, Universitätsklinikum Lübeck, Lübeck, Deutschland
| | - S Perner
- Institut für Pathologie, Universitätsklinikum Lübeck, Lübeck, Deutschland
- Pathologie, Forschungszentrum Borstel, Leibniz Lungenzentrum, Borstel, Deutschland
| | - N Hartmann
- Institut für Pathologie, Universitätsklinikum Mainz, Mainz, Deutschland
| | - W Roth
- Institut für Pathologie, Universitätsklinikum Mainz, Mainz, Deutschland
| | - A Jung
- Pathologisches Institut, LMU München, München, Deutschland
| | - T Kirchner
- Pathologisches Institut, LMU München, München, Deutschland
| | - K Schwamborn
- Institut für Pathologie, TU München, München, Deutschland
| | - N Pfarr
- Institut für Pathologie, TU München, München, Deutschland
| | - E Dahl
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - R Knüchel
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland
| | - N T Gaisa
- Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland.
| |
Collapse
|
9
|
Pfarr N, Boxberg M, Riedmann K, Jesinghaus M, Konukiewitz B, Glimm H, Jost P, Fröhling S, Weichert W. Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Hirsch B, Endris V, Lassmann S, Weichert W, Pfarr N, Schirmacher P, Kovaleva V, Werner M, Bonzheim I, Fend F, Sperveslage J, Kaulich K, Zacher A, Reifenberger G, Köhrer K, Stepanow S, Lerke S, Mayr T, Aust DE, Baretton G, Weidner S, Jung A, Kirchner T, Hansmann ML, Burbat L, von der Wall E, Dietel M, Hummel M. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. Virchows Arch 2018; 472:557-565. [PMID: 29374318 PMCID: PMC5924673 DOI: 10.1007/s00428-017-2288-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 12/05/2017] [Accepted: 12/19/2017] [Indexed: 12/12/2022]
Abstract
The simultaneous detection of multiple somatic mutations in the context of molecular diagnostics of cancer is frequently performed by means of amplicon-based targeted next-generation sequencing (NGS). However, only few studies are available comparing multicenter testing of different NGS platforms and gene panels. Therefore, seven partner sites of the German Cancer Consortium (DKTK) performed a multicenter interlaboratory trial for targeted NGS using the same formalin-fixed, paraffin-embedded (FFPE) specimen of molecularly pre-characterized tumors (n = 15; each n = 5 cases of Breast, Lung, and Colon carcinoma) and a colorectal cancer cell line DNA dilution series. Detailed information regarding pre-characterized mutations was not disclosed to the partners. Commercially available and custom-designed cancer gene panels were used for library preparation and subsequent sequencing on several devices of two NGS different platforms. For every case, centrally extracted DNA and FFPE tissue sections for local processing were delivered to each partner site to be sequenced with the commercial gene panel and local bioinformatics. For cancer-specific panel-based sequencing, only centrally extracted DNA was analyzed at seven sequencing sites. Subsequently, local data were compiled and bioinformatics was performed centrally. We were able to demonstrate that all pre-characterized mutations were re-identified correctly, irrespective of NGS platform or gene panel used. However, locally processed FFPE tissue sections disclosed that the DNA extraction method can affect the detection of mutations with a trend in favor of magnetic bead-based DNA extraction methods. In conclusion, targeted NGS is a very robust method for simultaneous detection of various mutations in FFPE tissue specimens if certain pre-analytical conditions are carefully considered.
Collapse
Affiliation(s)
- B Hirsch
- Campus Mitte, Institute of Pathology, Charité-University Medicine Berlin, Virchowweg 15, 10117, Berlin, Germany. .,German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
| | - V Endris
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Medicine Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany
| | - S Lassmann
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute for Surgical Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Breisacherstraße 115A, 79106, Freiburg, Germany
| | - W Weichert
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, Technical University Munich (TUM), Munich, Germany
| | - N Pfarr
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, Technical University Munich (TUM), Munich, Germany
| | - P Schirmacher
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Medicine Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany
| | - V Kovaleva
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute for Surgical Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Breisacherstraße 115A, 79106, Freiburg, Germany
| | - M Werner
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute for Surgical Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Breisacherstraße 115A, 79106, Freiburg, Germany
| | - I Bonzheim
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology and Neuropathology, University Hospital Tuebingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tuebingen, Germany
| | - F Fend
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology and Neuropathology, University Hospital Tuebingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tuebingen, Germany
| | - J Sperveslage
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology and Neuropathology, University Hospital Tuebingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076, Tuebingen, Germany
| | - K Kaulich
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Department of Neuropathology, Heinrich Heine University Duesseldorf and Biological and Medical Research Center (BMFZ), Genomics and Transcriptomics Laboratory, Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany
| | - A Zacher
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Department of Neuropathology, Heinrich Heine University Duesseldorf and Biological and Medical Research Center (BMFZ), Genomics and Transcriptomics Laboratory, Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany
| | - G Reifenberger
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Department of Neuropathology, Heinrich Heine University Duesseldorf and Biological and Medical Research Center (BMFZ), Genomics and Transcriptomics Laboratory, Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany
| | - K Köhrer
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Department of Neuropathology, Heinrich Heine University Duesseldorf and Biological and Medical Research Center (BMFZ), Genomics and Transcriptomics Laboratory, Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany
| | - S Stepanow
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Department of Neuropathology, Heinrich Heine University Duesseldorf and Biological and Medical Research Center (BMFZ), Genomics and Transcriptomics Laboratory, Heinrich Heine University Duesseldorf, 40225, Duesseldorf, Germany
| | - S Lerke
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
| | - T Mayr
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
| | - D E Aust
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
| | - G Baretton
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany
| | - S Weidner
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, Ludwig-Maximilians University Munich, Thalkirchner Straße 36, 80337, Munich, Germany
| | - A Jung
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, Ludwig-Maximilians University Munich, Thalkirchner Straße 36, 80337, Munich, Germany
| | - T Kirchner
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Institute of Pathology, Ludwig-Maximilians University Munich, Thalkirchner Straße 36, 80337, Munich, Germany
| | - M L Hansmann
- German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.,Dr. Senckenberg Institute of Pathology, University Hospital, Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - L Burbat
- Campus Mitte, Institute of Pathology, Charité-University Medicine Berlin, Virchowweg 15, 10117, Berlin, Germany.,German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - E von der Wall
- Campus Mitte, Institute of Pathology, Charité-University Medicine Berlin, Virchowweg 15, 10117, Berlin, Germany.,German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - M Dietel
- Campus Mitte, Institute of Pathology, Charité-University Medicine Berlin, Virchowweg 15, 10117, Berlin, Germany.,German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| | - M Hummel
- Campus Mitte, Institute of Pathology, Charité-University Medicine Berlin, Virchowweg 15, 10117, Berlin, Germany.,German Cancer Consortium (DKTK) Partner Site, and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| |
Collapse
|
11
|
Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS. Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis 2017; 6:e337. [PMID: 28504689 PMCID: PMC5523069 DOI: 10.1038/oncsis.2017.36] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 02/10/2017] [Accepted: 03/28/2017] [Indexed: 12/27/2022] Open
Abstract
Multiple myeloma (MM) is a plasma cell malignancy that is still considered to be incurable in most cases. A dominant mutation cluster has been identified in RAS/RAF genes, emphasizing the potential significance of RAS/RAF/MEK/ERK signaling as a therapeutic target. As yet, however, the clinical relevance of this finding is unclear as clinical responses to MEK inhibition in RAS-mutant MM have been mixed. We therefore assessed RAS/RAF mutation status and MEK/ERK pathway activation by both targeted sequencing and phospho-ERK immunohistochemistry in 180 tissue biopsies from 103 patients with newly diagnosed MM (NDMM) and 77 patients with relapsed/refractory MM (rrMM). We found a significant enrichment of RAS/BRAF mutations in rrMM compared to NDMM (P=0.011), which was mainly due to an increase of NRAS mutations (P=0.010). As expected, BRAF mutations were significantly associated with activated downstream signaling. However, only KRAS and not NRAS mutations were associated with pathway activation compared to RAS/BRAFwt (P=0.030). More specifically, only KRASG12D and BRAFV600E were consistently associated with ERK activation (P<0.001 and P=0.006, respectively). Taken together, these results suggest the need for a more specific stratification strategy consisting of both confirmation of protein-level pathway activation as well as detailed RAS/RAF mutation status to allow for a more precise and more effective application of targeted therapies, for example, with BRAF/MEK inhibitors in MM.
Collapse
Affiliation(s)
- J Xu
- Max Eder Group Experimental Therapies for Hematologic Malignancies, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.,Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - N Pfarr
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - V Endris
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - E K Mai
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - N H Md Hanafiah
- Max Eder Group Experimental Therapies for Hematologic Malignancies, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - N Lehners
- Max Eder Group Experimental Therapies for Hematologic Malignancies, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - R Penzel
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - W Weichert
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - A D Ho
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| | - P Schirmacher
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - H Goldschmidt
- Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.,National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - M Andrulis
- Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
| | - M S Raab
- Max Eder Group Experimental Therapies for Hematologic Malignancies, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
| |
Collapse
|
12
|
Loibl S, Pfarr N, Weber K, Villegas-Angel S, Stenzinger A, Furlanetto J, Budczies J, Marmé F, Denkert C, Weichert W. Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx142] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W. Abstract P2-03-09: Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-03-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Currently, breast cancer during pregnancy (BCP) is not believed to be biologically different from breast cancer unrelated to pregnancy based on limited datasets mainly obtained by immunohistochemistry. However, some groups report that BCP patients have an inferior survival compared to young non-pregnant breast cancer patients. The largest analysis based on the BCP registry by the German Breast Group (GBG) revealed however, no difference between pregnant and non-pregnant breast cancer patients, indicating that treatment rather than biology might be the reason for the inferior survival reported by others.
Methods: The BCP study (GBG 29/BIG 03-02) is a multicentre observational study for breast cancer during pregnancy. In tumour tissue collected within this study from pregnant M0 patients we investigated the following genes: AKT1, ATM, BRAF, CBFB, CCND1, CDH1, CDKN2A, CTCF, EGFR, ERBB2, ESR1, FGFR2, GATA3, KRAS, MAP2K4, MAP3K1, MDM2, MED12, MYC, PIK3CA, PIK3R1, PTEN, RB1, RUNX1, and TP53 by massive parallel sequencing (MPS). This included patients with all molecular subtypes: HR+/-, HER2+/-. Sequencing was done on an IonTorrent Proton using a custom designed Breast Cancer Panel (BCPv2). This panel comprises 236 amplicons split into two primer pools and covers hotspot regions of 138 exons of the 25 genes.
To test the hypothesis that breast cancer diagnosed during pregnancy is biologically not different from breast cancer diagnosed in young non-pregnant women, we compared the molecular profiles obtained, with genetic data from M0 patients not known to be pregnant from TCGA with age <= 45. TCGA data were pre-processed to be compatible to the targeted MPS datasets from pregnant patient.
Results: Material from 141 patients from the BCP study was available from which ultimately 109 fully evaluable MPS datasets could be obtained. In the TCGA data set 114 breast cancer patients <= 45 years could be identified. Pregnant patients with breast cancer were significantly younger, had more often HR- tumours (59.6% vs 30.1%) but had less frequently grade 3 tumours (30.6% vs 48.2%). All other clinical variables showed no significant differences between pregnant and non-pregnant patients. In the BCP data, overall 106 mutations could be found. The most frequent mutations were detected in TP53 (62%) and in PIK3CA (11.1%). In non-pregnant patients the mutation rates were different with 32.5% in TP53 and 21.1% in PIK3CA.
Exact matching by variables age, HR, HER2 and grade yielded 40 patients from both datasets. In these subcohorts, still divergent mutational rates for TP53 and PIK3CA between pregnant and non-pregnant women were noted, however, the differences failed to reach statistical significance.
Conclusions: Overall the mutational landscapes do not seem to be overtly different between pregnant patients and no-pregnant controls, although slight imbalances in mutational rates occurred, which might be partly explained by a selection bias and a small sample size after matching. Further comparisons using other datasets, looking into survival and regarding copy number variation are currently conducted.
This research is been funded by the German Cancer Consortium-DKTK and the BANSS Foundation.
Citation Format: Loibl S, Pfarr N, Weber K, Neunhöffer T, Villegas S, Stenzinger A, Furlanetto J, Aktas B, Budczies J, Marmé F, Kahmann L, Denkert C, Weichert W. Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-03-09.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - N Pfarr
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - K Weber
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - T Neunhöffer
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - S Villegas
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - A Stenzinger
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - J Furlanetto
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - B Aktas
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - J Budczies
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - F Marmé
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - L Kahmann
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - C Denkert
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| | - W Weichert
- German Breast Group, Neu-Isenburg; Insitute of Pathology, Technical University Munich; Helios Kliniken Wiesbaden, Wiesbaden; Institute of Pathology, Charité Berlin; Institute of Pathology, University Hospital Heidelberg; University Women´s Hopsital, Essen; NCT, Section Translational Gynaecologic Oncology, Heidelberg; Klinikum Landkreis Neumarkt
| |
Collapse
|
14
|
Loibl S, Budczies J, Weichert W, Furlanetto J, Stenzinger A, Pfarr N, von Minckwitz G, Jackisch C, Schneeweiss A, Fasching P, Schmatloch S, Aktas B, Nekljudova V, Weber K, Untch M, Denkert C. Abstract P3-07-03: PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Phosphatidylinositol 3-kinase mutations (PIK3CA) are common in breast cancer (BC). Mutations are predominantly found in hot-spots located in the helical and kinase domains (exons 9 and 20). We recently demonstrated that PIK3CA mutations predict lower pathological complete response (pCR) to double blockade with trastuzumab/lapatinib in HER2+ve primary BC.
Methods: We evaluated PIK3CA mutations in 293/403 HER2+ve tumors of participants of the neoadjuvant GeparSepto (G7) study (Untch et al. SABCS 2014). The G7 study investigated the effect of exchanging paclitaxel for nab-paclitaxel prior to EC. All patients received trastuzumab and pertuzumab. The G7 study showed a significantly higher pCR rate in patients receiving nab-paclitaxel. HER2, hormone receptors (HR), Ki67 and tumor infiltrating lymphocytes (TILs) were centrally assessed prior to randomization. PIK3CA mutations in exons 9 and 20 were evaluated in formalin-fixed, paraffin embedded core biopsies taken before therapy using deep targeted massive parallel sequencing with a minimum coverage of 500 and a mean coverage of 6520 and 6346 per amplicon, (exon9 and exon 20). Only non-synonymous mutations in the coding region that were called at variant allele frequency ≥10% were taken into consideration. Only cases with a tumor cell content of ≥20% were included.
Results: In the G7 study, 396 patients with HER2+ve BC have been randomized from 06/2012 to 01/2014 and started treatment. From these 293 could be sequenced. Median age in the analyzed cohort was 49 years (range 22-75); most tumors were cT1-2 (89.9%); cN0 (54.4%); ductal invasive (88.7%), grade 3 (53.9%), HR+ve (69.6%), Ki67>20% (69.3%), LPBC-negative (83.2%). Overall, 22.2% of the tumors were found to have a PIK3CA mutation, 20.1% in HR+ve and 27.0% in HR-ve. Overall, the pCR rate was significantly lower in the PIK3CA mutant tumors compared to the wild type (wt) group (47.7% vs. 66.7%; p=0.009). This effect was seen both in the HR+ve (43.9% vs. 61.3%; p=0.052) and the HR-ve population (54.2% vs. 80.0%; p=0.029). There was also a significant difference in pCR according to PIK3CA mutation status dependant on the taxane. In the nab-paclitaxel group, pCR rates were significantly lower in patients with PIK3CA mutations compared to those without PIK3CA mutations (38.7% vs. 72.0%; p=0.001), whereas in the paclitaxel group, there was no significant difference between patients with and without a PIK3CA mutation (55.9% vs. 60.9%; p=0.690). The respective interaction could be demonstrated in univariate (p=0.039) as well as multivariate regression analysis (p=0.010) after adjusting for known baseline factors.
Conclusion: Patients with PIK3CA mutant HER2+ve BC have a significantly lower pCR rate compared to patients with wt tumors. In contrast to the results with double anti-HER2 blockade consisting of trastuzumab/lapatinib, the effect was evident irrespective of the HR status. In addition, PIK3CA mutation status was significantly associated with higher pCR following nab-paclitaxel.
The project has partly been funded within the EU-FP7 project RESPONSIFY No 278659 and the German Cancer Consortium (DKTK).
Citation Format: Loibl S, Budczies J, Weichert W, Furlanetto J, Stenzinger A, Pfarr N, von Minckwitz G, Jackisch C, Schneeweiss A, Fasching P, Schmatloch S, Aktas B, Nekljudova V, Weber K, Untch M, Denkert C. PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer – Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-03.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - J Budczies
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - W Weichert
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - J Furlanetto
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - A Stenzinger
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - N Pfarr
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - P Fasching
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - S Schmatloch
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - B Aktas
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - V Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - K Weber
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| | - C Denkert
- German Breast Group, Neu-Isenburg, Germany; Charite University of Berlin, Berlin, Germany; University Hospital Heidleberg, Heidelberg, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Erlangen, Erlangen, Germany; Elisabeth Krankenhaus Kassel, Kassel, Germany; University Hospital Sen, Essen, Germany; Helios Kliniken Berlin-Buch, Berlin, Germany
| |
Collapse
|
15
|
Warth A, Endris V, Kriegsmann M, Stenzinger A, Penzel R, Pfarr N, Weichert W. [Molecular diagnostics of non-small cell lung cancer: New markers and technologies]. Pathologe 2015; 36:154-63. [PMID: 25820445 DOI: 10.1007/s00292-015-0004-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.
Collapse
Affiliation(s)
- A Warth
- Institut für Pathologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Deutschland
| | | | | | | | | | | | | |
Collapse
|
16
|
Pfarr N, Fischer C, Ehlken N, Becker-Grünig T, Schranz D, Gorenflo M, Hager A, Hinderhofer K, Nagel C, Grünig E. Genetische Untersuchungen bei Kindern mit idiopathischer, hereditärer und mit angeborenem Herzfehler assoziierter pulmonal arterieller Hypertonie. Pneumologie 2013. [DOI: 10.1055/s-0033-1334765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Fuchs O, Pfarr N, Pohlenz J, Thanner F, Schmidt H. Congenital hypothyroidism caused by a novel homozygous mutation in the thyroid peroxidase gene. J Pediatr Endocrinol Metab 2008; 21:1093-7. [PMID: 19189706 DOI: 10.1515/jpem.2008.21.11.1093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
UNLABELLED Congenital primary hypothyroidism occurs in one out of 4,000 births. About 20% of cases are due to defects in thyroid hormonogenesis. We report on a German girl with congenital hypothyroidism due to a mutation in the thyroid peroxidase (TPO) gene who had elevated serum levels of thyroglobulin during periods of hyperthyrotropinemia. METHODS The TPO gene was sequenced directly from genomic DNA. RESULTS The patient had a novel homozygous mutation (R314W) in the TPO gene. The unaffected parents were non-consanguineous and both heterozygous carriers of the mutation. Fifty normal individuals did not harbor the mutation ruling out a common polymorphism. CONCLUSION The identified TPO gene mutation (R314W) is very likely the genetic cause for hypothyroidism in the reported child. R314W has not been described before and codes for a presumably inactive TPO molecule.
Collapse
Affiliation(s)
- O Fuchs
- Dr. von Hauner University Children's Hospital, Pediatric Endocrinology and Medical Genetics, Munich, Germany
| | | | | | | | | |
Collapse
|
18
|
Bischofs C, Dittmar M, Kamalanabhaiah SR, Pfarr N, Ide M, Kanitz M, Kahaly GJ. Novel alleles of deoxyribonuclease in patients with endocrine autoimmunity and impaired DNase activity. Exp Clin Endocrinol Diabetes 2007. [DOI: 10.1055/s-2007-972520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
Fricke-Otto S, Pfarr N, Mühlenberg R, Pohlenz J. Mild congenital primary hypothyroidism in a Turkish family caused by a homozygous missense thyrotropin receptor (TSHR) gene mutation (A593 V). Exp Clin Endocrinol Diabetes 2006; 113:582-5. [PMID: 16320156 DOI: 10.1055/s-2005-865914] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Congenital primary hypothyroidism (CH) occurs in 1 of 4000 births. The majority of the cases are due to agenesis or dysgenesis of the thyroid gland, which can be caused by mutations in genes encoding for transcriptional factors that are responsible for the development of the thyroid gland. It is also known that the thyrotropin receptor (TSHR), a G-protein coupled receptor, is involved in late stages of thyroid organogenesis. Thus, mutations in the TSHR gene can cause congenital hypothyroidism. However, the clinical spectrum of thyroid abnormalities due to mutant TSHRs is wide and ranges from severe hypoplasia to an almost normal sized and structured thyroid gland. So far, 23 distinct loss-of-function mutations in the TSHR gene have been reported, occurring in families of different ethnic backgrounds and geographical areas. Here we report on a Turkish kindred in which two children were diagnosed to have very mild congenital primary hypothyroidism and one child had subclinical hypothyroidism. A novel homozygous missense mutation in codon 593 (A593 V) of the TSHR gene was identified in the affected individuals as the underlying molecular defect. This mutation substitutes a non-polar amino acid (alanine) with a non-polar amino acid (valine), so that only a minimal impairment of the TSHR function is expected. Indeed, the molecular finding is in agreement with the observed mild phenotype of the affected individuals. Our conclusion is that in mild primary hypothyroidism or subclinical hypothyroidism, mutations in the TSHR gene have to be considered as the molecular cause, especially in patients who have no detectable thyroid autoantibodies and have thyroid glands of normal size and in normal location.
Collapse
|